Group items tagged

London's Great Ormond Street Hospital and Alder Hey Children's Hospital in Liverpool are poised to introduce groundbreaking gender-related services in England, following the closure of the Gender Identity Development Service (Gids) operated by the Tavistock and Portman NHS Foundation Trust. Amid concerns expressed by hospital executives regarding the closure of Gids, with leaked emails revealing apprehensions about appointment cancellations and inadequate communication with the new services, the National Health Services England (NHSE) has confirmed "its commitment to ensuring continuity of care for patients already accessing endocrine care in GIDS." NHSE's decision to transition to regional services stems from a 2022 interim review, led by Dr. Hilary Cass, which highlighted the need for improved support structures for gender-distressed youth. It emphasized a significant increase in referrals to Gids, surpassing 5,000 in 2021/22, compared to less than 250 a decade ago.

Part of a raft of National Health Services (NHS) measures which aim to support people to prevent or reduce incidence of type 2 diabetes and obesity, the NHS Digital Weight Management Programme has emerged as a beacon of success in the battle against obesity, with a recent study showcasing its effectiveness in aiding weight loss among participants. According to research published in The Obesity Journal, the programme has garnered significant traction, with over 63,000 individuals referred in its inaugural year. Encouragingly, half of those referred opted to enroll in the service, highlighting its appeal and accessibility. Among the 14,000 participants who completed the 12-week programme between April 2021 and March 2022, a notable average weight loss of 3.9kg (equivalent to 8.59lbs) was achieved. Even among those who did not complete the programme, an average weight loss of 2.2kg (approximately 4.85lbs) was observed.

The NHS's latest report on ambulance services in England for March 2024 reveals significant progress in response times for emergency calls across all categories compared to recent months. The Ambulance Quality Indicators (AQI) Statistical Note, released in April, underscores both improvements and persistent challenges within the sector. Recent figures obtained from the Liberal Democratic party suggest ongoing struggles with response times, particularly for category two patients, which may include individuals experiencing strokes or heart attacks requiring a response within 18 minutes. Similarly, in November last year, ambulance waits for category 2 calls surged to their highest level since December 2022, reaching 93 minutes, after dropping to 32 minutes in January 2023 according to the British Heart Foundation. However, according to the latest statistical figures obtained from AQI, March 2024 witnessed the shortest average response times for all four categories of emergency calls since August 2023.

Adding to the growing evidence of global medicine shortages, a new study has revealed that the European generic medicines market is "not in shape" to help Europe meet its public health priorities. In the past decade, the rate of generic medicines withdrawals has risen by 12 per cent, while there has been a three per cent decrease in the launch of generic products, as per Teva Pharmaceuticals' recent analysis of IQVIA data. Within the mental therapeutic area, seven per cent of generic products disappeared between 2013 and 2023, while there was a seven per cent decrease in the availability of generic cancer medicines in just six years (2017-2022). These medicines were listed on the Union List of Critical Medicines to help avoid potential shortages, as the European Commission (EC) said this could cause "significant harm to patients and pose important challenges to health systems." While mature generic products constitute the majority of the List, they remain susceptible to withdrawals, despite containing products crucial for safeguarding Europe's public health, the Teva analysis report noted. Since 2013, the number of generic products for the treatment of schizophrenia and bipolar disorder has declined by 25 per cent, with Hungary and Bulgaria experiencing the biggest loss at 83 per cent and 58 per cent respectively.

Consumer healthcare group Haleon on Thursday announced that it has entered into a binding agreement for the sale of the ChapStick brand to Suave Brands Company, a company owned by American private equity firm Yellow Wood Partners. The British consumer healthcare company has agreed to sell its lip balm brand to Suave for about $430 million in cash and a minority interest in the buyer, valued at around $80 million. Haleon, which was spun off from the GSK Group in July 2022, said that cash proceeds from the sale would be used to pay down debt. ChapStick generated £112 million ($142.5 million) in revenue in 2023, said Haleon, adding that the sale is likely to close in the second quarter of 2024. Brian McNamara, Chief Executive Officer, Haleon, said: "Today's announcement is consistent with Haleon being proactive in managing our portfolio, and being rigorous and disciplined where there are opportunities for divestment. "While ChapStick is a great brand, much loved by consumers around the world, it is not a core focus for Haleon.

The STADA Health Report 2024, published today, has revealed a significant decline in satisfaction with national healthcare systems across Europe, with a notable drop seen in the UK, Germany, and Kazakhstan. According to the report, satisfaction with the UK's healthcare system dropped sharply by 11 percentage points in just one year, falling from 67 percent in 2023 to 56 percent in 2024, likely fuelled by "post-pandemic pressure on the National Health Service (NHS)." In 2020, satisfaction stood at 85 percent before declining to its current level. In terms of discontentment over healthcare, Britain is followed closely by Kazakhstan and Germany, where satisfaction fell by 10 and 8 percent respectively in one year. The 10th annual health report released by global healthcare leader STADA Arzneimittel AG, the parent company of Thornton & Ross, is based on a survey of over 46,000 respondents aged 18 to 99 across 32 countries, with around 2,000 respondents in each country. A continuous decline in satisfaction levels has been observed since 2021. Overall satisfaction with healthcare systems in Europe was recorded at 74 percent in 2020, just before the pandemic. This figure dropped to 71 percent in 2021, 64 percent in 2022, and 61 percent in 2023.

"The UK remains genuinely world-leading for life sciences in numerous areas - yet we continue to underperform on our potential," said Richard Torbett, Chief Executive of the Association of the British Pharmaceutical Industry (ABPI). His statement is based on recent government data indicating that the UK is not fully capitalizing on its strong historical and institutional advantages in life sciences across a range of economic, health, and research indicators. The latest 'Life sciences competitiveness indicators 2024' report from the government's Office for Life Sciences revealed that while the pharmaceutical industry leads in R&D spending with £9 billion in 2022, representing a fifth of total business investment, the country saw a notable decline in foreign direct investment (FDI), industry clinical trials, and exports. In 2023, FDI dropped by 21 per cent to £0.8 billion, following a trend that saw a 52 per cent decrease over the previous two years, including a £0.9 billion fall in FDI the year prior.

Technological innovation has touched our lives in immeasurable ways, from city infrastructure to personal entertainment and beyond. Even our health and conditions have been improved by the right tech innovations; contact lenses were one such innovation, having been safely pioneered as recently as the 19th century. But there are more recent developments which could change the lives of contact lens users forever; what are they? Smart Touch Contact Lenses While Smart Touch lenses are a relatively simple innovation, it is often the simple innovations that have the most fundamental impact on contact lens users. Smart Touch lenses are a new type of contact lens produced with a breathable material to promote eye health throughout the day. The key innovation lies in the packaging; Smart Touch contact lenses are provided in a bespoke blister packaging solution that delivers the lenses face-up. This ensures that the user never needs to touch the inner surface of the lens, keeping it hygienic and allowing for quick, unobtrusive application. These contact lenses provide innovative solutions for lens-wearers, and represent the power of slight technological improvements to existing products.

People rarely take care of their eyesight until they have an issue with it. Regular eye exams are necessary regardless of your age or physical condition. Your eyesight may vary over time, and some of those changes may prompt you to consider visiting an Eye Clinic in Miami for an eye checkup.